Article

Congruence of the current practices in Hymenoptera venom allergic patients in Poland with EAACI guidelines

Department of Pediatrics, Polish-American Children's Hospital, Jagiellonian University Medical College, Krakow, Poland.
Archives of medical science : AMS 10/2011; 7(5):832-9. DOI: 10.5114/aoms.2011.25558
Source: PubMed

ABSTRACT Venom immunotherapy (VIT) practice is the definitive treatment for patients with potentially fatal allergic reactions to Hymenoptera stings. The aim is assesing compliance of VIT practice in Poland with the current European Academy of Allergy and Clinical Immunology (EAACI) guidance.
A multicentre study was carried out using a structured questionnaire which was sent by post to all VIT practitioners in Poland. Some questionnaire items were altered, in comparison to original version by adding additional answer options or alowing multiple answer option. The response rate was 100%. The obtained results were compared with the published EAACI guidelines.
Twenty-six Polish centres took part in the survey. SSIgE and skin prick tests (SPT) are together used as the first line of investigation, whereas confirmatory intradermal tests (IDT) are applied in half of centres. Only a few centres measure baseline serum tryptase levels. The ultra-rush protocol is preferred. Antihistamine pre-medication is routinely practiced. A target dose equal to 100 µg is used in most centres. A 6-week interval between booster doses is the most frequent. Five years is considered as an optimal VIT duration. Before the VIT completion, SSIgE is evaluated in fifty percent of centres, whereas sting challenge is considered by half of responders.
There are some differences between current practice in Poland and the EAACI recommendations, indicating areas requiring better compliance. Comparision between Poland and the United Kingdom revealed that health service organization and health care funding may play a major role in the provision of allergy services. This may affect the extent to which international guidance may be applied in individual countries. It is worth considering conducting the same survey in other European countries.

Download full-text

Full-text

Available from: Grzegorz Lis, Jun 16, 2015
1 Follower
 · 
122 Views
  • 01/2012; 6:451-455. DOI:10.5114/pdia.2012.32393
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Venom allergy, though rare, may seriously influence health-related quality of life (HRQoL). There is a paucity of research on HRQoL of adolescents and young adults with Hymenoptera venom allergy. The aim was to assess the level of HRQoL and to evaluate its independent predictors in Polish adolescents and young adults treated with venom immunotherapy. A multicenter cross-sectional study based on the Vespid Allergy Quality of Life Questionnaire (VQLQ) adapted for Polish adolescents was used. The study sample included 87 patients (14-21 years) studied at different stages of venom immunotherapy (VIT). Statistical analysis was done with multivariate linear regression. Anxiety level was higher in patients with 4(th) grade of Mueller's classification (anaphylactic shock) than in those with 3(rd) grade (B = 0.84, 95% CI = 0.07-1.61, p = 0.03). Caution increased along with an increase of anxiety of adolescents treated with VIT (B = 0.54, 95% CI = 0.39-0.68, p < 0.01). Level of limitations increased with increasing caution of adolescents (B = 0.63, 95% CI = 0.35-0.91, p < 0.01). Discomfort increased along with a rise of caution of patients (B = 0.38, 95% CI = 0.22-0.55, p < 0.01). Similarly, it increased with an increase of their feeling of limitations (B = 0.37, 95% CI = 0.23-0.51, p < 0.01). The level of discomfort in adolescents treated with VIT was lower in those who were treated with conventional protocol in comparison to those treated with rush or ultra-rush ones (B = -0.47, 95% CI = -0.90 - -0.03, p = 0.04). Severity of anaphylactic reaction is an independent determinant of anxiety level in adolescents treated with VIT. The VIT protocol affects HRQoL of treated patients.
    Archives of Medical Science 12/2012; 8(6):1076-82. DOI:10.5114/aoms.2012.32419 · 1.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hymenoptera venom allergy is common and can be very severe. The only effective preventive treatment is venom immunotherapy. The terms of diagnostic assessment and indications for treatment are based on guidelines from 2005 which need to be updated and, moreover, recent surveys have shown that current practices vary in spite of these guidelines. We wanted to make proposals to update guidelines on the diagnosis of hymenoptera allergy, in order to improve and standardize practices. We based our work on an extended analysis of the literature since publication of the EAACI guidelines and on the opinion of a working group from the French Society of Allergology. This work has allowed us to expand the indications for diagnostic assessment and reminds us that diagnosis requires intradermal skin tests and specific IgE assays, to which we can add the use of recombinant allergens and basal serum tryptase levels. The basophil activation test and reciprocal inhibition assays are considered as clinically useful and should be standardized and made available.
    Revue Française d'Allergologie 05/2014; DOI:10.1016/j.reval.2014.01.031 · 0.35 Impact Factor